ReviewNPJ vaccines2023
Emerging vaccine strategies against the incessant pneumococcal disease.
Review in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Knowledge, attitudes, and beliefs of pharmacists regarding vaccinations against influenza and pneumococci - a systematic review.Human vaccines & immunotherapeutics · 2025Pooled it
- Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial.Human vaccines & immunotherapeutics · 2026Trial
- A MultinuclearACS omega · 2026Article
- Review
- High-throughput antigen discovery using Functional Genomic Vaccinology (FGV) identifies protective Streptococcus pneumoniae vaccine candidates.Nature communications · 2026Article
- Biofilm formation during pneumococcal carriage imprints naturally acquired humoral immunity.PLoS pathogens · 2026Article
- Pneumococcal membrane particles promote serotype-independent cellular and humoral immunity and protect against pneumococcal colonization.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- Characterization of a novel monoclonal antibody candidate that targets bacterial GAPDH and protects neonatal mice from infections caused byAntimicrobial agents and chemotherapy · 2026Article
- Trimodulin supports antibacterial defence and restricts inflammation in preclinical pneumonia models.The European respiratory journal · 2026Article
- Development and Validation of a Functional Antibody Assay for Evaluating Protein-Based Pneumococcal Vaccines.Vaccines · 2026Article
- Article
- Pneumococcal conjugate vaccines and antimicrobial resistance: serotype replacement, clonal dynamics, and future vaccine perspectives.Frontiers in immunology · 2026Review
- Article
- Biofilm formation during pneumococcal carriage imprints naturally acquired humoral immunity.bioRxiv : the preprint server for biology · 2025Article
- Erratum: Pneumococcal Vaccination of Adults in Italy: What Strategies?Journal of preventive medicine and hygiene · 2025Article
- Burden of Pneumococcal Disease and Adult Vaccination Landscape: An Overview with Data and Policy Insights from Türkiye.Infectious diseases & clinical microbiology · 2025Review
- A narrative review on the effectiveness of PPSV23 vaccination in adults in China.Human vaccines & immunotherapeutics · 2025Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The incidence of invasive pneumococcal disease (IPD) caused by infection with the pathogen Streptococcus pneumoniae (Spn) has been on a downward trend for decades due to worldwide vaccination programs. Despite the clinical successes observed, the Center for Disease Control (CDC) reports that the continued global burden of S. pneumoniae will be in the millions each year, with a case-fatality rate hovering around 5%. Thus, it is a top priority to continue developing new Spn vaccination strategies to harness immunological insight and increase the magnitude of protection provided. As emphasized by the World Health Organization (WHO), it is also crucial to broaden the implementation of vaccines that are already obtainable in the clinical setting. This review focuses on the immune mechanisms triggered by existing pneumococcal vaccines and provides an overview of the current and upcoming clinical strategies being employed. We highlight the associated challenges of serotype selectivity and using pneumococcal-derived proteins as alternative vaccine antigens.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.